Endovascular Engineering, a Menlo Park, CA-based a preclinical stage firm creating mechanical thrombectomy options to deal with peripheral indications, raised $15M in Sequence A1 funding.
The spherical was led by Santé Ventures and Cordis.
The corporate intends to make use of the funds to advance its thrombectomy platform by means of preliminary scientific analysis.
Led by CEO Mike Rosenthal and Founder and CSO Dr. Luis Savastano, Endovascular Engineering develops thrombectomy gadgets to deal with sufferers with Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). The E2 thrombectomy system was invented by Dr. Luis Savastano and developed in partnership with Inventure Group LLC, a Menlo Park primarily based medical system incubator centered on creating subsequent technology medical gadgets to fulfill the wants of sufferers and the physicians that deal with them.